NORWOOD, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator, announced the start of cannabis product manufacturing in Missouri. MariMed’s award-winning products are expected to be available across the state in time for the holidays.
“Expanding our branded products into Missouri has been a key goal for us,” said Ryan Crandall, Chief Revenue Officer. “Missouri’s fast-growing market is eager for high-quality products, and we expect to start sales and distribution by the end of November.”
MariMed plans a statewide wholesale push, distributing its popular edibles and vapes, including Betty’s Eddies
This expansion brings MariMed’s operations to six states, with facilities also in Delaware, Illinois, Maryland, Massachusetts, and Ohio. MariMed will manage the Missouri facility under a Managed Services Agreement (MSA) until license transfer approval.
About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty’s Eddies
For MariMed Investors
Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, MariMed Inc.’s expectations concerning management’s plans, objectives, and strategies, including its plans to continue to expand its footprint in the Commonwealth of Massachusetts to the maximum allowed by state regulations. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MariMed undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by MariMed, see the disclosure contained in our public filings with the Securities and Exchange Commission including, without limitation, our most recent Annual Report on Form 10-K.
Investor Relations Contact:
Steve West
Vice President, Investor Relations
Email: ir@marimedinc.com
Phone: (781) 277-0007
Company Contact:
Howard Schacter
Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007
Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow